REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
=== Everton === On 20 July 2021, Townsend signed for fellow English club Everton on a two-year contract upon the expiry of his contract with Crystal Palace. Townsend made his debut on 14 August 2021, assisting Richarlison's goal as Everton came from behind to beat Southampton 3–1 on the opening day of the season. On 24 August 2021, Townsend scored the winning goal in an EFL Cup round two fixture against Huddersfield Town. On 13 September 2021, Townsend scored his first Premier League goal for Everton, smashing in a long-range effort from 30 yards to put Everton ahead as they went on to beat Burnley 3–1; this goal won him the Premier League Goal of the Month award. On 20 March 2022, Townsend was forced off the pitch in the 16th minute of an eventual 4–0 loss against former club Crystal Palace in the quarter-finals of the FA Cup, and was later revealed to have suffered an anterior cruciate ligament injury. Subsequently, he went on to miss the remainder of the 2021–22 season as well as the entirety of the 2022–23 season, after which he departed Everton at the conclusion of his contract, having not played in over 18 months.
Patients with heart disease, and patients who smoked cigarettes, were less likely to survive. Another trial, the Stem Cell Transplant vs. Cyclophosphamide (SCOT) trial, is ongoing. Asengeprast is an experimental systemic scleroderma drug candidate. It is a small molecule inhibitor of the G-protein coupled receptor GPR68 with antifibrotic activity.
Most synthesis routines yield a mix of actinide isotopes as oxides, from which a given isotope of curium needs to be separated. An example procedure could be to dissolve spent reactor fuel (e.g. MOX fuel) in nitric acid, and remove the bulk of the uranium and plutonium using a PUREX (Plutonium – URanium EXtraction) type extraction with tributyl phosphate in a hydrocarbon. The lanthanides and the remaining actinides are then separated from the aqueous residue (raffinate) by a diamide-based extraction to give, after stripping, a mixture of trivalent actinides and lanthanides. A curium compound is then selectively extracted using multi-step chromatographic and centrifugation techniques with an appropriate reagent. Bis-triazinyl bipyridine complex has been recently proposed as such reagent which is highly selective to curium. Separation of curium from the very chemically similar americium can also be done by treating a slurry of their hydroxides in aqueous sodium bicarbonate with ozone at elevated temperature. Both americium and curium are present in solutions mostly in the +3 valence state; americium oxidizes to soluble Am(IV) complexes, but curium stays unchanged and so can be isolated by repeated centrifugation. Metallic curium is obtained by reduction of its compounds. Initially, curium(III) fluoride was used for this purpose. The reaction was done in an environment free of water and oxygen, in an apparatus made of tantalum and tungsten, using elemental barium or lithium as reducing agents.
Most rattlesnake species mate during the summer or fall, while some species mate only in the spring, or during both the spring and fall. Females secrete small amounts of sex pheromones, which leave a trail the males follow using their tongues and Jacobson's organs as guides. Once a receptive female has been located, the male often spends several days following her around (a behavior not common outside of the mating season), frequently touching and rubbing her in an attempt to stimulate her. The males of some species, such as timber rattlesnakes (C. horridus), fight each other during the mating season, in competition over females. These fights, known as "combat dances", consist of the two males intertwining the anterior portion of their bodies, often with their heads and necks held vertically. The larger males usually end up driving the smaller males away. Although many kinds of snakes and other reptiles are oviparous (lay eggs), rattlesnakes are ovoviviparous (give birth to live young after carrying eggs inside). The female produces the ova ("eggs") in her ovaries, after which they pass through her body cavity and into one of her two oviducts. The ova are arranged in a continuous chain in a coiled section of the oviduct, known as the "tuba". Male rattlesnakes have sexual organs known as hemipenes, located in the base of the tail. The hemipenis is retracted inside of the body when mating is not occurring. The hemipenis is similar to the human penis.
Sources: en.wikipedia.org
In March 1946, the government of Kimon Georgiev was reorganized—two ministries were added, the number of sub-chairmen was reduced, and there were personnel changes and changes in the proportions of the coalition parties. This was on the orders of Joseph Stalin, who criticised the Bulgarian communists for the slow imposition of the totalitarian regime in the country. He demanded the strengthening of the presence of the BPC and BZNS in the cabinet, the removal of the foreign minister Petko Staynov and a purge of the foreign ministry staff, and the replacement of the finance minister Stancho Cholakov. Despite the pressure against Zveno, Georgiev himself retained the confidence of Stalin and Georgi Dimitrov and remained at the head of the cabinet. Apart from being prime minister, he remained a minister without portfolio. On Joseph Stalin's direct instructions to Georgi Dimitrov, a purge in the army began in the summer of 1946, accompanied by public show trials against alleged officer organizations - "Tsar Krum", "Neutral Officer" and others, as well as opposition leaders such as G. M. Dimitrov and Krustyo Pastukhov. These were coordinated with the parallel mounted trial in Yugoslavia against Draža Mihailović, during which Mihailović's links with Bulgarian public figures such as G. М. Dimitrov, Asen Stamboliyski and the war minister Damyan Velchev. In this setting, Kimon Georgiev publicly spoke out in support of the Military Union and personally of Damyan Velchev, whom he called his "closest and most inseparable personal friend, political associate and comrade in the cabinet".
Once released into the air, VOCs can undergo reactions with ozone and hydroxyl radicals to produce other VOCs, such as formaldehyde. Health effects include eye, nose, and throat irritation; headaches, loss of coordination, nausea; and damage to the liver, kidney, and central nervous system. Testing emissions from building materials used indoors has become increasingly common for floor coverings, paints, and many other important indoor building materials and finishes. Indoor materials such as gypsum boards or carpet act as VOC 'sinks', by trapping VOC vapors for extended periods of time, and releasing them by outgassing. The VOCs can also undergo transformation at the surface through interaction with ozone. In both cases, these delayed emissions can result in chronic and low-level exposures to VOCs. Several initiatives aim to reduce indoor air contamination by limiting VOC emissions from products. There are regulations in France and in Germany, and numerous voluntary ecolabels and rating systems containing low VOC emissions criteria such as EMICODE, M1, Blue Angel and Indoor Air Comfort in Europe, as well as California Standard CDPH Section 01350 and several others in the US. Due to these initiatives an increasing number of low-emitting products became available to purchase.
D-dimer increases with age. It has therefore been suggested to use a cutoff equal to patient's age in years × 10 μg/L (or x 0.056 nmol/L) for patients aged over 50 years for the suspicion of venous thromboembolism (VTE), as it decreases the false positive rate without substantially increasing the false negative rate. An alternative measurement of D-dimer is in fibrinogen equivalent units (FEU). The molecular weight of the fibrinogen molecule is about twice the size of the D-dimer molecule, and therefore 1.0 mcg/mL FEU is equivalent to 0.5 mcg/mL of d-dimer.
Sources: en.wikipedia.org
Postprandial somnolence (colloquially known as food coma or after-meal dip) is a benign state of drowsiness or lassitude following a meal, a general state of sleepiness and low energy related to activation of the parasympathetic nervous system in response to mass in the gastrointestinal tract. While there are numerous theories surrounding this behavior, such as decreased blood flow to the brain, neurohormonal modulation of sleep through digestive coupled signaling, or vagal stimulation, very few have been explicitly tested. To date, human studies have loosely examined the behavioral characteristics of postprandial sleep, demonstrating potential shifts in EEG spectra and self-reported sleepiness. To date, the only clear animal models for examining the genetic and neuronal basis for this behavior are the fruit fly, the mouse, and the nematode Caenorhabditis elegans.
== Scientific contributions == Meir Wilchek is known for his research in the field of biorecognition or affinity phenomenon, and its various application, e.g. for affinity chromatography, affinity labeling, affinity therapy, and the avidin-biotin system. The avidin-biotin complex is the highest affinity interaction in nature, and its utilization to biochemistry integrates all of the former approaches. Other contributions include conversion of serines to cysteines, and was the first to prove experimentally the equation of Forster on dependence of energy transfer on distance, an approach known today as FRET. He also studied the fine structure of these chromophores using circular dichroism. More recently, he participated in a research team who studied how garlic works at the molecular level, thanks to a unique biotechnological procedure for producing large quantities of pure allicin, garlic's main biologically active component.
The composition of Euryapsida was uncertain. Ichthyosaurs were, at times, considered to have arisen independently of the other euryapsids, and given the older name Parapsida. Parapsida was later discarded as a group for the most part (ichthyosaurs being classified as incertae sedis or with Euryapsida). However, four (or three if Euryapsida is merged into Diapsida) subclasses remained more or less universal for non-specialist work throughout the 20th century. It has largely been abandoned by recent researchers: In particular, the anapsid condition has been found to occur so variably among unrelated groups that it is not now considered a useful distinction.
=== Professional === Lisa attended her first IFBB professional competition at the 2014 Tampa Pro, where she placed 16th place. In 2015, Alina Popa became her coach and started training at the Armbrust PRO Gym. Her training paid off when she went on to win the 2015 Omaha Pro, the first time a professional British female bodybuilder won an overall professional competition since 1999.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.